TeresaTrades Posted - 1 day ago

Heavy options volume $XLB $FEZ $JNPR $NOV $KD

Slim2020 Posted - 2 days ago

$SMCI $Nov 19 (Reuters) - Shares of Super Micro Computer (SMCI.O), opens new tab soared nearly 30% in premarket trading on Tuesday, after the server maker sought an extension from Nasdaq for its delayed financial filings and appointed a new auditor as it looks to avoid being delisted. Super Micro announced the appointment of BDO USA as its independent auditor, effective immediately, less than a month after Ernst & Young resigned after it raised concerns about the company's governance, transparency and internal control over financial reporting.

NVSTly Posted - 3 days ago

| NEW ENTRY IDEA $NFLX: Trade Setup Two potential OUTCOMES and TARGETS in play! I'm taking PUTS with targets at $820.04 and $817.15. Buying SNFLX 820 PUT, 22 $NOV 24 as soon as the market opens. Posted by @AlertsWolf Delay: 5 min

UncleStock Posted - 3 days ago

$WHD $HP $HAL $NOV suggested for $OSX US PHLX Oil Service - value screen: https://zpr.io/t58fg

Estimize Posted - 1 week ago

Wall St is expecting 0.37 EPS for $NOV Q4 [Reporting 02/05 AMC] http://www.estimize.com/intro/nov?chart=historical&metric_name=eps&utm_cont

UncleStock Posted - 1 week ago

$WHD $HP $HAL $NOV suggested for $OSX US PHLX Oil Service - value screen: https://zpr.io/t58fg

insiderbuyingselling Posted - 1 week ago

$NOV new insider selling: 73256 shares. http://insiderbuyingselling.com/?t=NOV

NRG8 Posted - 1 week ago

$EBS Will $EBS do a deal with $LLY or $NOV to use the world class Bayview facility to manufacture weight loss drugs? "Analysts believe the anti-obesity market is shaping up to be one of the most lucrative opportunities in the history of the pharmaceutical sector, potentially worth as much as $100 billion or more by the end of the decade. Novo Nordisk and Eli Lilly, enjoy a virtual duopoly on the sector and both are working hard to fend off upstart competitors like Viking Therapeutics with a pipeline of new drugs and new formulations like pills, as well as bolstering their supply chains to address ongoing shortages." .

TeresaTrades Posted - 10/30/24

Largest CALL OI decreases $MSTR $COIN $WSC $VFC $NOV

Shazad768 Posted - 10/30/24

@BestRegards 💯 agree, we’re cannibalising into $LLY & $NOV. It’s going to be interesting on Monday

swingingtech Posted - 10/29/24

$EA $NOV $INCY https://wallstreetwaves.com/noteworthy-tuesday-option-activity-ea-nov-incy/

TeresaTrades Posted - 10/29/24

Heavy options volume $EWC $AMKR $WSC $NOV $CVI

Thestocktraderhubzee Posted - 10/28/24

WATCHLIST OCT 29 2024. $AVTR Wells Fargo Maintains Overweight on Avantor, Lowers Price Target to $28 $NOV TD Cowen Maintains Buy on NOV, Lowers Price Target to $22 $BCDA HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target $CRGY Stephens & Co. Maintains Overweight on Crescent Energy, Raises Price Target to $16 $ELAN Barclays Maintains Overweight on Elanco Animal Health, Lowers Price Target to $19

anachartanalyst Posted - 10/28/24

$NOV https://anachart.com/wp-content/uploads/ana_temp/1730127711_soc-img.jpg

Elevator_up Posted - 10/28/24

$VKTX $LLY $NOV Clear articulation of the key points regarding the Compounding Pharmacy issue - r/t the FDA Shortage List designation. Very Big money is involved. 💰 Lawsuit by Big Pharma in place. ✔️ • Viking - L & S ✅ “The FDA is currently in the middle of reevaluating the decision to take tirzepatide off the shortage list and has proposed a status update to the district judge on Nov. 21. This is the first time the FDA's removal of a drug from the shortage list has been challenged.” https://finance.yahoo.com/news/why-compounders-and-telehealth-providers-are-undeterred-by-the-potential-end-of-the-weight-loss-drug-shortage-154743126.html

FilingFact Posted - 10/26/24

New financial insights available on https://www.filingfact.com/ from yesterdays report of $NOV With the launch of the new platform we are offering 1 month of FREE Premium Access (worth $49) to the first 100 users! 🥳 💬 We’d love to hear your thoughts—your feedback will help us improving our service to your needs! For any questions, ideas, or support, reach out to us at [email protected] 👉 Join today and be a part of the journey!

swingingtech Posted - 10/24/24

$NOV $AVPT https://wallstreetwaves.com/nov-inc-nov-fails-to-meet-q3-earnings-and-revenue-expectations/

xsiddiqmx Posted - 10/24/24

$NOV missed by 8%

BourlaBeliever Posted - 10/24/24

$NOV seems like they forgot it was earnings day

BourlaBeliever Posted - 10/24/24

$NOV are they gonna release them?

DonCorleone77 Posted - 10/24/24

$NOV National Oilwell options imply 4.3% move in share price post-earnings Pre-earnings options volume in National Oilwell is normal with calls leading puts 7:3. Implied volatility suggests the market is anticipating a move near 4.3%, or 65c, after results are released. Median move over the past eight quarters is 3.6%.

Justinian Posted - 10/24/24

$NOV looking below 15 to add

rockieshomeowner Posted - 10/23/24

$NOV Is this going lower towards $10 or higher towards $20 in next 12 months?

xsiddiqmx Posted - 1 month ago

$NOV time to reverse.

Doozio Posted - 1 month ago

🐑 say it’s cheap! Bahhhht NOW it’s $nov ember.

JClem_Stocks Posted - 1 month ago

$NOV worth adding here and lower for the move up. These prices are cheap…

Thestocktraderhubzee Posted - 1 month ago

WATCHLIST OCT 04 2024.. $ICE B of A Securities Maintains Buy on Intercontinental Exchange, Raises Price Target to $175 $AMAT Wells Fargo Maintains Overweight on Applied Mat, Lowers Price Target to $235 $EBAY Wells Fargo Maintains Equal-Weight on eBay, Raises Price Target to $63 $NOV JP Morgan Maintains Overweight on NOV, Lowers Price Target to $22 $RIOT Cantor Fitzgerald Reiterates Overweight on Riot Platforms, Maintains $22 Price Target

youngstocktrade Posted - 1 month ago

$NOV long!

bingchilling7 Posted - 1 month ago

$NOV is a good value stock

DonCorleone77 Posted - 09/24/24

$NOV Wells Fargo cuts NOV Inc. to Underweight, sees market conditions as unfavorable Wells Fargo downgraded NOV Inc. to Underweight from Equal Weight with a price target of $16, down from $20 as part of a broader research note on Energy Servieces. The firm notes that the current market conditions are unfavorable to a meaningful upswing in orders for the company and that equipment companies are likely to lag peers against an overall backdrop of declining capex intensity and modest D&C activity recovery, the analyst tells investors in a research note. E&P companies continue to favor efficiency gains, cost-cutting ,and right-sizing over growth, and as such, NOV's traditional onshore and offshore drilling rig customers should restrain their capex investments for the next several years, the firm added.